Klein Pavel, Tyrlikova Ivana, Mathews Gregory C
From the Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD.
Neurology. 2014 Nov 18;83(21):1978-85. doi: 10.1212/WNL.0000000000001004. Epub 2014 Oct 29.
We review adjunctive ketogenic diet (KD) and modified Atkins diet (MAD) treatment of refractory epilepsy in adults. Only a few studies have been published, all open-label. Because of the disparate, uncontrolled nature of the studies, we analyzed all studies individually, without a meta-analysis. Across all studies, 32% of KD-treated and 29% of MAD-treated patients achieved ≥ 50% seizure reduction, including 9% and 5%, respectively, of patients with >90% seizure frequency reduction. The effect persists long term, but, unlike in children, may not outlast treatment. The 3:1 and 4:1 [fat]:[carbohydrate + protein] ratio KD variants and MAD are similarly effective. The anticonvulsant effect occurs quickly with both diets, within days to weeks. Side effects of both diets are benign and similar. The most serious, hyperlipidemia, reverses with treatment discontinuation. The most common, weight loss, may be advantageous in patients with obesity. Potential barriers to large-scale use of both diets in adults include low rate of diet acceptance and high rates of diet discontinuation. The eligible screened/enrolled subject ratios ranged from 2.9 to 7.2. Fifty-one percent of KD-treated and 42% of MAD-treated patients stopped the diet before study completion. Refusal to participate was due to diet restrictiveness and complexity, which may be greater for KD than MAD. However, long-term adherence is low for both diets. Most patients eventually stop the diet because of culinary and social restrictions. For treatment of refractory status epilepticus, only 14 adult cases of KD treatment have been published, providing insufficient data to allow evaluation. In summary, KD and MAD treatment show modest efficacy, although in some patients the effect is remarkable. The diets are well-tolerated, but often discontinued because of their restrictiveness. In patients willing to try dietary treatment, the effect is seen quickly, giving patients the option whether to continue the treatment.
我们回顾了成人难治性癫痫的辅助生酮饮食(KD)和改良阿特金斯饮食(MAD)治疗。仅发表了少数研究,均为开放标签研究。由于这些研究性质各异且缺乏对照,我们对所有研究进行了单独分析,未进行荟萃分析。在所有研究中,接受KD治疗的患者中有32%、接受MAD治疗的患者中有29%癫痫发作减少≥50%,其中癫痫发作频率降低>90%的患者分别为9%和5%。这种效果长期持续,但与儿童不同的是,可能不会在治疗结束后仍持续存在。3:1和4:1[脂肪]:[碳水化合物+蛋白质]比例的KD变体和MAD同样有效。两种饮食的抗惊厥作用在数天至数周内迅速出现。两种饮食的副作用都是良性的且相似。最严重的副作用高脂血症在停药后可逆转。最常见的副作用体重减轻,对肥胖患者可能有益。在成人中大规模使用这两种饮食的潜在障碍包括饮食接受率低和饮食中断率高。符合条件的筛查/入组受试者比例在2.9至7.2之间。接受KD治疗的患者中有51%、接受MAD治疗的患者中有42%在研究完成前停止了饮食。拒绝参与是由于饮食限制和复杂性,KD可能比MAD更大。然而,两种饮食的长期依从性都很低。大多数患者最终因烹饪和社交限制而停止饮食。对于难治性癫痫持续状态的治疗,仅发表了14例成人KD治疗病例,提供的数据不足以进行评估。总之,KD和MAD治疗显示出适度的疗效,尽管在一些患者中效果显著。这两种饮食耐受性良好,但常因限制性而中断。对于愿意尝试饮食治疗的患者,效果很快显现,使患者能够选择是否继续治疗。